Bss — Competitive Intelligence Brief

Bss (SODIUM CITRATE) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: sodium citrate. Area: Cardiovascular.

marketed sodium citrate Calcium Cardiovascular Small molecule

Target snapshot

Bss (SODIUM CITRATE) — B Braun. ANTICOAGULANT CITRATE DEXTROSE SOLUTION USP (ACD) SOLUTION A prevents blood clotting by binding free calcium, a crucial co-factor in the clotting cascade.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Bss TARGET	SODIUM CITRATE	B Braun	marketed	sodium citrate	Calcium	1980-01-01
Trodelvy	sacituzumab-govitecan	Immunomedics Inc	marketed		Tumor-associated calcium signal transducer 2	2020-01-01
Levoamlodipine	LEVAMLODIPINE		marketed	levamlodipine	Voltage-gated L-type calcium channel	2019-01-01
Horizant	GABAPENTIN ENACARBIL	Azurity	marketed	Anti-epileptic Agent	Voltage-dependent calcium channel subunit alpha-2/delta-1	2011-01-01
Jakafi	RUXOLITINIB	Incyte Corp	marketed		Ankyrin repeat and protein kinase domain-containing protein 1, Bone morphogenetic protein receptor type-1B, Calcium/calmodulin-dependent protein kinase type IV	2011-01-01
Cleviprex	CLEVIDIPINE	Chiesi	marketed	Dihydropyridine Calcium Channel Blocker [EPC]	Voltage-dependent L-type calcium channel subunit alpha-1C	2008-01-01
Sensipar	CINACALCET	Amgen	marketed	Calcium-sensing Receptor Agonist	Extracellular calcium-sensing receptor	2004-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (sodium citrate class)

1. B Braun · 1 drug in this class